lipomatosis: an autosomal dominant condition in which multiple lipomas are present on the body. Many discrete, encapsulated lipomas form on the trunk and extremities, with relatively few on the head and shoulders.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
113 |
4. Check minimum number of eventsNone |
113 |
5. Include endpointsNone |
113 |
6. Filter based on genotype QC (FinnGen only) |
107 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E88
- Name in latin
- Lipomatosis non alibi classificata
Similar endpoints
↥List of similar endpoints to
Lipomatosis, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Other metabolic disorders
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 515 | 278 | 233 |
| Only index persons | 487 | 269 | 218 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 53.98 | 54.63 | 53.59 |
| Only index persons | 54.26 | 54.83 | 53.56 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 107 | 63 | 44 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 57.68 | 57.23 | 58.33 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 109
- Matched controls
- 1090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E88.2
ICD-10 Finland
Lipomatosis, not elsewhere classified
+∞
155.2
109
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
8.1
14.6
22
33
M48.0
ICD-10 Finland
Spinal stenosis
5.5
13.0
31
74
D17.1
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk
17.4
12.3
19
13
N03AX12
ATC
[U] gabapentin; oral
4.3
10.5
34
103
A01
ICPC
Pain general/multiple sites
5.2
10.5
25
59
R5140
NOMESCO Finland
Monitoring the use of the aid
4.9
10.3
27
69
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.0
10.1
39
134
N03AX16
ATC
[U] pregabalin
3.9
10.1
42
152
E66.8
ICD-10 Finland
Other obesity
11.1
9.7
18
19
N02AX02
ATC
tramadol; systemic, rectal
3.6
9.6
67
337
A10BA02
ATC
metformin; oral
3.4
8.3
44
183
M54.5
ICD-10 Finland
Low back pain
3.2
8.3
57
277
L17
ICPC
Foot/toe symptom/complaint
3.2
8.1
48
214
L03
ICPC
Low back symptom/complaint
3.2
8.1
47
207
D17.2
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of limbs
16.6
7.9
12
8
C03CA01
ATC
furosemide; systemic
3.3
7.9
42
175
E66.01
ICD-10 Finland
Obesity due to excess calories
4.4
7.8
22
59
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.3
7.6
38
152
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.9
7.6
26
81
D17.7
ICD-10 Finland
Benign lipomatous neoplasm of other sites
+∞
7.4
7
*
A10BK01
ATC
dapagliflozin; oral
6.3
7.3
19
35
D17.9
ICD-10 Finland
Benign lipomatous neoplasm, unspecified
32.4
7.3
9
*
H02AB06
ATC
prednisolone; systemic
3.0
7.0
66
373
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.0
7.0
49
236
R06.0
ICD-10 Finland
Dyspnoea
3.1
7.0
41
179
103
Kela drug reimbursment
Diabetes, insulin-treated
3.1
6.9
38
160
T90
ICPC
Diabetes non-insulin dependent
3.0
6.6
38
163
A10BJ06
ATC
semaglutide; parenteral
7.4
6.6
15
23
A10BH01
ATC
sitagliptin; oral
4.2
6.5
19
52
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
3.4
6.5
28
101
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.8
6.4
22
68
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
4.2
6.2
18
49
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
3.4
6.2
26
92
M54.4
ICD-10 Finland
Lumbago with sciatica
3.0
6.1
33
136
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
57
312
2.73
6.23
4.7
3.7
11.50
5.38
mg/mmol
0.28
42
186
43
225
2.50
4.91
2.1
1.7
1.00
1.29
mg/l
0.36
37
175
65
418
2.37
4.61
2.4
1.9
97.19
100.44
pmol/l
0.16
38
212
66
428
2.37
4.58
11.3
6.3
1.21
1.21
mmol/l
0.12
60
365
95
735
3.28
4.47
5.8
4.3
14.21
14.78
pmol/l
1.35
86
667
15
46
3.62
4.37
13.2
7.1
25.23
24.46
mmol/l
0.32
15
46
11
22
5.43
4.13
4.1
2.3
24.60
26.37
mmol/l
0.44
11
22
76
547
2.29
3.83
12.4
10.6
5.23
3.84
e9/l
1.40
65
482
29
143
2.40
3.64
2.7
1.7
—
—
—
0
0
22
97
2.59
3.48
3.4
3.4
—
—
—
0
0
10
26
4.13
3.07
1.2
1.3
—
—
—
0
0
15
58
2.84
3.02
5.6
2.7
5.18
5.26
kpa
0.12
15
58
22
104
2.40
3.00
2.5
1.6
—
—
—
0
0
23
112
2.34
2.94
13.8
6.1
103.61
104.15
mmol/l
0.27
23
112
70
518
1.98
2.90
9.6
6.8
8.73
11.04
umol/l
3.36
70
493
21
100
2.36
2.81
2.3
1.7
—
—
—
0
0
61
434
1.92
2.81
2.1
1.9
1.97
1.33
mmol/l
2.60
53
359
42
264
1.96
2.79
1.7
1.5
18.22
20.85
nmol/l
0.48
36
213
14
56
2.72
2.65
1.6
1.5
—
—
—
0
0
12
44
2.94
2.64
1.3
1.1
—
—
—
0
0
104
935
3.45
2.54
6.6
5.0
6.22
5.85
mmol/l
1.78
98
870
27
152
2.03
2.40
7.3
2.3
2.01
0.78
e6/l
0.57
16
80
12
48
2.69
2.27
3.2
1.7
—
—
—
0
0
88
736
2.02
2.20
11.7
8.0
78.30
76.85
u/l
0.22
88
698
24
134
2.01
2.18
8.0
2.6
4.00
2.90
e6/l
0.14
13
63
67
516
1.77
2.18
6.5
3.3
0.00
0.00
estimate
-0.00
14
112
15
69
2.36
2.16
8.8
3.2
2.27
1.63
mmol/l
0.21
15
57
68
528
1.77
2.13
6.5
3.4
0.00
0.00
estimate
-0.00
14
109
9
31
3.07
2.13
2.6
2.9
—
—
—
0
0
34
217
1.82
2.08
2.8
2.5
—
—
—
0
0
38
251
1.79
2.08
8.4
2.7
0.30
0.51
e6/l
0.57
30
172
67
523
1.73
2.01
6.5
3.4
0.00
0.00
estimate
-0.00
14
115
7
22
3.33
1.91
1.9
1.1
—
—
—
0
0
26
158
1.85
1.84
1.8
1.6
1119.98
1233.37
nmol/l
0.28
19
118
29
183
1.80
1.82
2.0
1.8
411.19
463.19
pmol/l
0.53
21
159
48
353
1.64
1.73
4.2
3.2
81.46
28.98
ng/l
0.41
37
232
102
933
2.45
1.73
27.2
13.5
79.25
81.73
ml/min/173m2
0.46
97
870
8
31
2.70
1.69
1.4
1.5
0.25
0.21
g/l
—
8
31
10
41
2.58
1.69
12.1
4.0
25.25
24.18
mmol/l
—
10
41
8
32
2.62
1.63
1.4
1.5
1.27
1.11
g/l
—
8
32
6
20
3.11
1.60
2.0
1.5
—
—
—
0
0
6
21
2.96
1.53
2.0
1.1
—
—
—
0
0
32
219
1.65
1.49
1.4
1.3
15.61
35.86
iu/ml
—
7
65
7
28
2.60
1.48
1.3
1.3
—
—
—
0
0
11
53
2.20
1.44
16.1
6.8
93.22
92.99
%
0.05
11
53
18
105
1.86
1.44
3.8
5.3
239.94
240.91
u/l
0.01
18
100
14
75
1.99
1.42
4.1
2.4
66.29
70.21
ml/min/173m2
—
7
28
11
54
2.15
1.38
16.1
6.7
1.28
1.52
%
0.39
11
54
5
17
3.03
1.37
4.0
1.7
9.16
5.28
pmol/l
—
5
17
6
24
2.58
1.32
1.0
2.5
154.67
228.92
pmol/l
—
6
24
22
141
1.70
1.30
6.1
3.7
0.82
0.81
mmol/l
0.23
22
134
6
25
2.48
1.26
2.2
1.3
—
—
—
0
0
69
582
1.51
1.22
3.0
3.1
—
—
—
0
0
101
940
2.01
1.14
28.8
13.8
21.01
21.66
mg/l
0.09
93
748
7
32
2.27
1.10
1.4
2.1
30.14
42.84
nmol/l
—
7
32
5
21
2.44
1.10
1.6
1.2
—
—
—
0
0
50
406
1.43
1.02
5.6
3.2
0.00
0.00
estimate
-0.00
13
93
7
35
2.07
1.02
2.6
1.6
—
—
—
0
0
29
212
1.50
1.01
5.0
3.7
1.02
1.02
kg/l
0.57
21
131
7
37
1.95
0.96
2.6
1.8
—
—
—
0
0
52
433
1.38
0.89
3.4
2.9
—
—
estimate
—
0
0
6
30
2.06
0.88
1.5
1.6
—
—
—
0
0
9
53
1.76
0.78
19.4
6.6
0.53
0.63
%
—
9
53
5
25
2.05
0.73
2.2
1.4
—
—
—
0
0
5
26
1.97
0.71
2.8
3.1
3.40
2.62
index
—
5
13
18
129
1.47
0.69
2.7
1.7
29.57
29.26
s
0.15
18
123
5
28
1.82
0.67
2.4
1.6
—
—
—
0
0
37
304
1.33
0.66
4.7
2.8
0.00
0.01
estimate
0.49
12
91
20
148
1.43
0.66
1.5
1.5
—
—
—
0
0
25
193
1.38
0.65
1.1
1.3
0.86
8.69
u/ml
—
7
73
12
80
1.56
0.63
2.3
1.4
—
—
—
0
0
0
23
0.00
0.59
0.0
1.7
—
810.71
—
0
18
0
15
0.00
0.41
0.0
1.4
—
17.46
—
0
15
14
109
1.33
0.35
1.2
5.0
2.31
7.75
ug/l
—
9
86
20
240
0.80
0.35
5.4
4.6
22.10
20.72
%
—
6
120
6
46
1.32
0.33
13.7
1.8
1.07
1.58
%
—
6
46
6
46
1.32
0.33
1.2
1.0
—
—
—
0
0
34
307
1.16
0.24
6.1
3.5
0.00
0.00
estimate
-0.00
13
104
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
13.27
—
0
11
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
10
80
1.28
0.21
6.2
4.1
1.23
1.23
mmol/l
—
10
69
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
3.4
—
181.33
—
0
12
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
0.95
—
0
14
0
14
0.00
0.20
0.0
1.4
—
1.28
—
0
8
0
14
0.00
0.20
0.0
1.4
—
0.98
—
0
8
0
14
0.00
0.20
0.0
1.4
—
1.10
—
0
8
9
81
1.12
0.15
1.9
2.2
—
—
—
0
0
5
44
1.14
0.10
1.6
1.8
—
—
—
0
0
17
186
0.90
0.10
2.4
3.1
0.31
0.72
ug/l
6.96
11
114
5
46
1.09
0.10
3.2
1.3
—
—
—
0
0
10
88
1.15
0.08
2.1
2.4
—
—
—
0
0
12
110
1.10
0.05
10.7
6.8
—
—
—
0
0
13
121
1.08
0.04
6.9
4.5
32.13
33.65
%
—
8
75
18
172
1.06
0.02
1.9
1.7
—
—
—
0
0
29
296
0.97
0.00
4.8
5.2
1.00
3.02
ug/l
1.25
29
268
78
782
0.99
0.00
37.3
16.9
13.73
13.63
%
0.33
78
775
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
410.40
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
47.71
—
0
7
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_LIPOMATOSIS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_LIPOMATOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_LIPOMATOSIS – Lipomatosis, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data